key: cord-0853267-88ugfy3d
authors: Bahadur Gurung, Arun; Ajmal Ali, Mohammad; Lee, Joongku; Abul Farah, Mohammad; Mashay Al-Anazi, Khalid; Sami, Hiba
title: Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and in silico COVID-19 drug candidate molecules
date: 2021-09-17
journal: Saudi J Biol Sci
DOI: 10.1016/j.sjbs.2021.09.042
sha: 5978df37913ffb2f3bdc9384169eec0ca752a02b
doc_id: 853267
cord_uid: 88ugfy3d

Human serum albumin (HSA) is the most prevalent protein in the blood plasma which binds an array of exogenous compounds. Drug binding to HSA is an important consideration when developing new therapeutic molecules, and it also aids in understanding the underlying mechanisms that govern their pharmacological effects. This study aims to investigate the molecular binding of coronavirus disease 2019 (COVID-19) therapeutic candidate molecules to HSA and to identify their putative binding sites. Binding energies and interacting residues were used to evaluate the molecular interaction. Four drug candidate molecules (β-D-N4-hydroxycytidine, Chloroquine, Disulfiram, and Carmofur) demonstrate weak binding to HSA, with binding energies ranging from -5 to -6.7 kcal/mol. Ivermectin, Hydroxychloroquine, Remdesivir, Arbidol, and other twenty drug molecules with binding energies ranging from -6.9 to -9.5 kcal/mol demonstrated moderate binding to HSA. The strong HSA binding drug candidates consist of fourteen molecules (Saquinavir, Ritonavir, Dihydroergotamine, Daclatasvir, Paritaprevir etc.) with binding energies ranging from -9.7 to -12.1 kcal/mol. All these molecules bind to different HSA subdomains (IA, IB, IIA, IIB, IIIA, and IIIB) through molecular forces such as hydrogen bonds and hydrophobic interactions. Various pharmacokinetic properties (gastrointestinal absorption, blood-brain barrier permeation, P-glycoprotein substrate, and cytochrome P450 inhibitor) of each molecule were determined using SwissADME program. Further, the stability of the HSA-ligand complexes was analyzed through 100 ns molecular dynamics simulations considering various geometric properties. The binding free energy between free HSA and compounds were calculated using Molecular mechanics Poisson–Boltzmann surface area (MM/PBSA) and molecular mechanics generalized Born surface area (MM/GBSA) approach.The findings of this study might be useful in understanding the mechanism of COVID-19 drug candidates binding to serum albumin protein, as well as their pharmacodynamics and pharmacokinetics.

In December 2019, Wuhan, Hubei Province, China, reported numerous cases of a new respiratory disease. By January 2020, it had been proven that these illnesses were caused by a new coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS- and the disease came to be known as coronavirus disease 2019 (COVID-19) (Ashour et al., 2020) . SARS-CoV-2 is a new betacoronavirus that shares 79 % of its genome sequence with severe acute respiratory syndrome coronavirus (SARS-CoV) and 50% similarity with Middle East respiratory syndrome coronavirus (MERS-CoV) (Lu et al., 2020) . It has a genomic structure that is similar to that of other betacoronaviruses. The six functional open reading frames (ORFs) are replicase (ORF1a/ORF1b), spike (S), envelope (E), membrane (M), and nucleocapsid (N) in order from 5′ to 3′. Between the structural genes, there are additional seven potential ORFs encoding accessory proteins (Chan et al., 2020) . The demand for new antiviral drugs against SARS-CoV-2 continues as the COVID-19 pandemic spreads quickly (Villamagna et al., 2020) . There is currently insufficient evidence that any antiviral drugs available today may effectively treat COVID-19 pneumonia. However, numerous clinical trials on possible antiviral treatments are now underway (Zhaori et al., 2020) . The antiviral treatments can be classified into two groups-the one that targets the coronavirus, either by inhibiting a key viral enzyme involved in genome replication or by preventing its entry into human cells and the second that is intended to influence the human immune system, either by enhancing the innate response against viruses or by suppressing the inflammatory processes that lead to lung damage (Tu et al., 2020) . The majority of these drugs were developed for different infections before being repurposed for COVID-19. The method of repurposing existing antiviral agents authorized or under development for other viral diseases has been embraced in light of the necessity to discover an effective treatment for symptomatic individuals . The SOLIDARITY study, an international clinical trial, was recently initiated by the World Health Organization (WHO) to address this issue. Lopinavir and ritonavir, with interferon β and chloroquine, and remdesivir are among the drugs tested in this study (Uddin et al., 2020) . These drugs like others need to bind to the drug carrier protein known as human serum albumin which influences their activity and half-life.

Human serum albumin (HSA) is a single-chain, non-glycosylated polypeptide with a molecular weight of 66,500 Da and 585 amino acids (Yamasaki et al., 2013) . The structure of HSA indicates the existence of three domains, namely domains I (residues 1-195), , and III (384-585), which are not only topologically identical but also have comparable three-dimensional structures, as anticipated by amino acid sequence comparison (He and Carter, 1992; Yang et al., 2014) . The polypeptide chain has an approximate dimension of 80×80×30 Å and forms a heart-shaped structure (Sugio et al., 1999) . Except for Cys34 (in domain I), HSA has 35 cysteine residues, all of which are involved in disulfide bond formation, which helps to stabilize the protein. Interdomain and inter-subdomain interactions have a crucial role in the stability of the HSA molecule, according to crystallographic evidence (Yamasaki et al., 2013) . It is the most abundant protein in blood plasma that serves a variety of important physiological functions. HSA controls colloidal osmotic pressure and transports a variety of endogenous substances such as fatty acids (FA), hormones, bile acids, amino acids, metals, and toxic metabolites, among others (Yang et al., 2014) . Furthermore, through binding with HSA, a wide range of drugs are transported to their target organs/tissues (Yamasaki et al., 2013) . As a result, HSA not only sequesters bound pharmaceuticals from oxidation and impacts drug distribution in vivo, but it also changes drug pharmacokinetic and pharmacodynamic characteristics (Tayyab and Feroz, 2020) .

HSA's remarkable ability to bind a wide range of drugs is one of its most distinguishing features (Yang et al., 2014) . Given the large quantity of HSA in plasma, drug binding affinity to HSA is an essential consideration when developing novel therapies. Furthermore, the interaction of drugs that bind to HSA at the same time might alter HSA binding behaviour and potentially affect the drugs' therapeutic efficacy (Tesseromatis and Alevizou, 2008) . The structures of HSA-ligand complexes have shown not only where distinct drug binding sites on HSA are located, but also reveal how several drugs interact with HSA (Yang et al., 2013 (Yang et al., , 2012 . When studying the processes determining the pharmacological effects of these molecules, understanding drug binding characteristics to HSA is critical (Yang et al., 2014) .

In this study, the molecular mechanism underlying the interaction between drug candidate molecules for COVID-19 and human serum albumin was investigated. The interaction between the drug candidate molecules and HSA was evaluated in terms of binding energies and binding site identification through molecular docking studies. The pharmacokinetic properties of the COVID-19 drug candidate molecules were also computationally investigated. The dynamic behaviour of the free HSA and HSA-ligand complexes were further explored through molecular dynamics simulations in an aqueous environment.

A total of 55 chemical structures were downloaded from PubChem database (Kim et al., 2016) which comprises 16 experimental drug candidate molecules for COVID-19 (Set A) (Caly et al., 2020; Choy et al., 2020; Dai et al., 2020; Devaux et al., 2020; Jin et al., 2020; K. Y. Wang et al., 2020; M. Wang et al., 2020; X. Wang et al., 2020) , 26 in silico drug candidate molecules for COVID-19 i.e. 15 molecules in Set-B from others' publications (Beck et al., 2020; Hall Jr and Ji, 2020; Ho, 2020; Ke et al., 2020; Pant et al., 2020) , 11 molecules in Set C from our previous publications (Gurung et al., 2020a (Gurung et al., , 2020b (Gurung et al., , 2020c , and 13 control drug molecules that bind serum albumin proteins (Set D) (Varshney et al., 2010) . The compounds that lacked a 3D structure were transformed using OpenBabel version 2.4.1 (O'Boyle et al., 2011) and optimized with the MMFF94 force field (Halgren, 1996) .

The three-dimensional X-ray crystal structure of human serum albumin was obtained from Protein Data Bank (http://www.rcsb.org/) using PDB ID: 6HSC. The structure consists of human serum albumin in complex with Aristolochic acid at a resolution of 1.9 Å.

The binding of COVID-19 drug candidate molecules to HSA was studied using AutoDock Vina program which is based on a sophisticated gradient optimization method (Trott and Olson, 2010) . The serum protein was prepared by removing the heteroatoms such as ions, 

Various pharmacokinetic properties (gastrointestinal absorption, blood-brain barrier permeation, P-glycoprotein substrate, and cytochrome P450 inhibitor) of each molecule were determined using SwissADME tool (Daina et al., 2017) .

The trajectories of the free HSA and HSA-ligand complexes were studied through 100 ns of MD simulations using GROningen MAchine for Chemical Simulations (GROMACS) 2019.2 software (Hess et al., 2008) with GROMOS96 43a1 force field. The free HSA and the HSAligand complexes were prepared for MD simulation by considering a cubic box of 1 Å spacing and solvated with simple point charge (SPC216) waters. A leap-frog time integration algorithm was used for integrating Newton's equations of motion. The systems were neutralized by adding an appropriate number of counterions and subsequently energy minimized. The systems were heated to 300 K and equilibrated for 100 ps in NVT (Number of particles, Volume and Temperature) ensemble and another 100 ps in NPT ensemble (Number of particles, Pressure and Temperature). After heating and equilibration, the systems were subjected to production MD run for 100 ns in NPT ensemble. PRODRG web server (Schüttelkopf and Van Aalten, 2004 ) was used to generate topology of the ligand. MD analysis was performed by choosing parameters such as RMSD (root mean square deviation), RMSF (root mean square fluctuation), Rg (radius of gyration), total SASA (solvent accessible surface area) and the number of hydrogen bonds (NHBs). Graphs were plotted using Xmgrace tool.

The binding free energy (ΔGbind) of the compounds was calculated using LARMD program (Yang et al., 2020) which uses the following equation (Equation 1). (1) where ΔE bind is the binding energy, TΔS sol is the solvation entropy and TΔS conf is the conformational entropy. While entropy was computed using an empirical method (Hao et al., 2009; Pan et al., 2008) , the enthalpy was derived using the Molecular mechanics Poisson-Boltzmann surface area (MM/PBSA) or molecular mechanics generalized Born surface area (MM/GBSA) method (Hou et al., 2011) .

A total of 55 molecules comprising of experimental (N=16, Set A1-A16) and in silico COVID-19 drug candidate molecules (N=26) which include set B17-B31 (N=15) and set C32-C42 (N=11) along with the control drugs (known binders of HSA) (N=13, set D43-D55) were docked into the human serum albumin protein using the blind docking method ( Figure   1 ). The molecular docking results of the compounds are represented in Table 1 . On comparing the binding energy scores with the control data set (-7 to -9.3 kcal/mol), the selected COVID-19 drug candidate molecules were classified into three different categoriesweak, moderate and strong binding molecules. Four drug candidate molecules viz., binding energies ranging from -9.7 to -12.1 kcal/mol. All these molecules bind to different HSA subdomains (IA, IB, IIA, IIB, IIIA, and IIIB) ( Table 1) through molecular forces such as hydrogen bonds and hydrophobic interactions. The Carmofur (A13) binds to HSA with a binding energy of -6.7 kcal/mol and the HSA_A13 complex is stabilized by a hydrogen bond with Ser480 and hydrophobic interactions through Gly328, Lys212, Ala213, Leu327, Ala210, Val482, Leu347, Lys351, Leu331, Ala350, Val216 (Figure 2A ). The Bonducellpin D (C34) binds to HSA with a binding energy of -7.9 kcal/mol and the HSA_C34 complex interaction occurs through four hydrogen bonds with Glu153, Ser192, Gln196 and His288 and hydrophobic interactions through Lys199, Lys195, Ala291, Phe157, Glu292, Glu188, Asp451 ( Figure 2B ). The compound 11b (A16) binds to HSA with a binding energy of -10.4 kcal/mol and the HSA_A16 complex is stabilized through two hydrogen bonds with Trp214 and Asp451 and hydrophobic interactions through Lys195, Lys199, Val482, Ala210, Ser480, Ser202, Leu481, Ser454, Leu457, Leu453, Glu450, Arg485, Val344, Leu198 ( Figure 2C ).

The control Indomethacin (D43) binds to HSA with a binding energy of -8.6 kcal/mol and the HSA_D43 interaction is facilitated through one hydrogen bond with Ser287 and hydrophobic interactions through Leu260, Ile290, Ala291, Lys199, Arg222, Val241, Trp214, Arg257, His242, Leu238 and Ala261 ( Figure 2D ). The pharmacokinetic properties such as gastrointestinal absorption, blood-brain barrier permeation, P-glycoprotein substrate, and cytochrome P450 inhibitor which play a significant role in absorption, distribution, metabolism, excretion, and toxicity (ADMET) were calculated for each molecule ( Table 2 ).

The free HSA and HSA-ligand-bound complexes (HSA_A13, HSA_C34, HSA_A16 and HSA_D43) were subjected to 100 ns of MD simulation to determine the stability of their trajectories. The geometric properties analysed in the study include RMSD, RMSF, Rg, SASA and NHB (Table 3) . Root mean square deviation (RMSD) computes the average distance between the backbone atoms of starting structure (reference structure) with (Table 3) . Table 4 . In each of the HSAligand complexes, van der Waals energy is the dominant force of molecular interactions. The top ten residues which contribute significantly towards the binding interaction between A13

and HSA include Arg209, Leu347, Ala213, Leu327, Ala210, Lys351, Gly328, Leu331, Ala350 and Val482 ( Figure 8A ). In case of HSA_C34 complex, residues such as Gln196, Lys195, Trp214, Ser192, Arg257, Tyr150, Leu238, Glu292, Lys199 and Phe149 has higher contributions ( Figure 8B ). The major residues contributing towards the binding interaction between A16 and HSA include Glu450, Trp214, Ser454, Leu481, Lys199, Val344, Leu198, Lys195, Arg485 and Leu457 ( Figure 8C ). In case of HSA_D43 complex, residues such as Arg257, Leu238, Leu260, Ser287, Ile290, Leu219, Ala291, Arg222, Ala261 and Ile264 has higher contribution to the total binding energy ( Figure 8D ).

There is a high paucity of new antiviral drugs against the COVID-19 pandemic which is caused by a novel betacoronavirus known as SARS-CoV-2. Numerous clinical trials on possible antiviral treatments are still underway and the majority of these drug candidate molecules are the repurposed drugs. The drug molecules in the body are bound to the drug carrier protein know as human serum albumin which influences their activity and half-life. In the process of developing novel therapies, the binding affinity of the drugs towards HSA is an important parameter of study given the large quantity of HSA in plasma. In addition, the therapeutic efficacy of drugs is altered upon binding to HSA (Tesseromatis and Alevizou, 2008) . Human serum albumin (HSA) is a non-glycosylated polypeptide with a molecular weight of 66,500 Da (Yamasaki et al., 2013) . The polypeptide chain forms a heart-shaped structure with a dimension of approximately 80×80×30 Å and (Sugio et al., 1999) . The presence of three domains, namely domains I (residues 1-195), , and III (384-585) are structural characteristics of HSA (He and Carter, 1992; Yang et al., 2014) . In our studies, we have characterized the binding energy and putative binding sites of selected anti- isothermal titration calorimetry (ITCs) and surface plasmon resonance (SPR) which will provide further insights into the binding of COVID-19 drug candidate molecules to HSA.

Human serum albumin (HSA) is an important drug carrier protein that modulates the activity and half-life of the majority of drug molecules. Using molecular docking and dynamics simulation techniques, we were able to characterize the binding sites of the selected experimental and in silico COVID-19 drug candidates. Our study unravels that these drug molecules bind to different domains of HSA using intermolecular forces such as hydrogen 

others, 2020. Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks. Pathogens 9

Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drugtarget interaction deep learning model

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

others, 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors

Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme

Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 Mpro enzyme through in silico approach

Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94

A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease

Understanding the mechanism of drug resistance due to a codon deletion in protoporphyrinogen oxidase through computational modeling

Atomic structure and chemistry of human serum albumin

GRGMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation

Addressing COVID-19 drug development with artificial intelligence

Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations

Structure of M pro from SARS-CoV-2 and discovery of its inhibitors

Artificial intelligence approach fighting COVID-19 with repurposing drugs

PubChem Substance and Compound databases

LigPlot+: multiple ligand-protein interaction diagrams for drug discovery

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Open Babel: An open chemical toolbox

Modeling the catalysis of anti-cocaine catalytic antibody: competing reaction pathways and free energy barriers

Peptide-like and small-molecule inhibitors against Covid-19

PRODRG: a tool for high-throughput crystallography of protein--ligand complexes

Drug repurposing approach to fight COVID-19

Crystal structure of human serum albumin at 2.5 Åresolution

Serum albumin: clinical significance of drug binding and development as drug delivery vehicle

The role of the protein-binding on the mode of drug action as well the interactions with other drugs

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

A review of SARS-CoV-2 and the ongoing clinical trials

SARS-CoV-2/COVID-19: viral genomics, epidemiology, vaccines, and therapeutic interventions

Ligand binding strategies of human serum albumin: how can the cargo be utilized?

The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective

Structure of Mpro from COVID-19 virus and discovery of its inhibitors

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

others, 2020. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro

Albumin--drug interaction and its clinical implication

Regulation of amantadine hydrochloride binding with IIA subdomain of human serum albumin by fatty acid chains

Interactive associations of drug--drug and drug--drug--drug with IIA subdomain of human serum albumin

Interactive association of drugs binding to human serum albumin

The authors report no conflicts of interest in this work.

The authors would like to extend their sincere appreciation to the Researchers Supporting Project number (RSP-2021/154), King Saud University, Riyadh, Saudi Arabia.

The domain I of HSA consists of subdomains IA coloured green (residues 5-107) and IB coloured orange (residues 108-196); domain II comprises subdomains IIA coloured blue (residues 197-297) and IIB coloured yellow (residues 298-383); domain III has subdomains IIIA coloured magenta (residues 384-497) and IIIB coloured cyan (residues 498-582). Hydrophobic interactions are shown as semi-arcs with red eyelashes, whereas hydrogen bonds are shown as green dashed lines. 

The authors report no conflicts of interest in this work.